Legend: Palais des congrès de Montréal = CC, Le Westin Montréal = W, Intercontinental Montréal = I
A * preceding a session name means that the session is an applied session.
A ! preceding a session name means that the session reflects the JSM meeting theme.
A * preceding a session name means that the session is an applied session.
A ! preceding a session name means that the session reflects the JSM meeting theme.
Activity Details
|
|
Tweet | ||
| 208 * ! | Mon, 8/5/2013, 2:00 PM - 3:50 PM | CC-516d | |
| Impact of Bayesian Methods in Medical Product Development — Invited Papers | |||
| Biopharmaceutical Section , International Society for Bayesian Analysis (ISBA) , ASA Special Interest Group for Medical Devices and Diagnostics , Pharmaceutical Statistics | |||
| Organizer(s): Karen Lynn Price, Eli Lilly and Company | |||
| Chair(s): Nelson Kinnersley, Roche Products Limited | |||
| 2:05 PM | An Overview of Current State of Bayesian Methods in Medical Product Development — Fanni Natanegara, Eli Lilly and Company ; Beat Neuenschwander, Novartis Pharma AG | ||
| 2:30 PM | Assessing Drug Safety Using Bayesian Evidence Synthesis — David I. Ohlssen, Novartis Pharmaceuticals Corporation ; Amy Xia, Amgen | ||
| 2:55 PM | The Use of Historical Information in Clinical Trials — Scott M. Berry, Berry Consultants ; Kert Viele, Berry Consultants | ||
| 3:20 PM | Discussant: Lisa LaVange, Food and Drug Administration, CDER | ||
| 3:40 PM | Floor Discussion | ||
2013 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.